Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 18, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

Cell therapy for neonatal hypoxic-ischemic encephalopathy.

Pedro M Pimentel-Coelho1, Rosalia Mendez-Otero

  • 1Instituto de Ciências Biomédicas, Instituto de Biofísica Carlos Chagas Filho and Programa de Terapia Celular, UFRJ, Rio de Janeiro, Brazil. pedrompc@biof.ufrj.br

Stem Cells and Development
|November 18, 2009
PubMed
Summary

Stem cell therapies show promise for treating neonatal hypoxic-ischemic encephalopathy (HIE), a condition causing neurological disability. Research in animal models suggests potential for neuroprotection and regeneration, but clinical translation requires further investigation.

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multitarget Strategy for Treatment of Pulmonary Arterial Hypertension: Combination of Mesenchymal Cells with Novel PDE-4 Inhibitor.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Correction: Mesentier-Louro et al. Time-Dependent Nerve Growth Factor Signaling Changes in the Rat Retina During Optic Nerve Crush-Induced Degeneration of Retinal Ganglion Cells. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 98.

International journal of molecular sciences·2026
Same author

Monocytes in neonatal stroke and hypoxic-ischemic encephalopathy: Pathophysiological mechanisms and therapeutic possibilities.

Neuroprotection (Chichester, England)·2025
Same author

Mesenchymal stem/stromal cells overexpressing leukemia inhibitory factor (LIF) promote arteriogenesis and functional recovery in a mouse model of critical hindlimb ischemia.

Stem cell research & therapy·2025
Same author

Regional modulation of neurodegeneration and microglial activation by intravenous Wharton's jelly mesenchymal stromal cell therapy in a mouse model of amyotrophic lateral sclerosis.

Neuroscience·2025
Same author

Isolation and characterization of canine umbilical cord mesenchymal/stromal stem cells.

In vitro cellular & developmental biology. Animal·2025

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Neonatal Neurology

Background:

  • Neonatal hypoxic-ischemic encephalopathy (HIE) is a significant cause of childhood neurological deficits.
  • Current supportive care for HIE has limitations, with no specific treatments available.
  • Stem/progenitor cell therapies are being explored for neuroprotection and regeneration in various neurological conditions.

Purpose of the Study:

  • To critically review existing studies on stem/progenitor cell transplantation in animal models of HIE.
  • To discuss the therapeutic potential of different stem cell types, including their mechanisms of action.
  • To explore the endogenous regenerative capacity of neural stem/progenitor cells (NSCs) in the context of HIE and consider cell therapies for prematurity-related encephalopathy.

Main Methods:

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Related Experiment Videos

Last Updated: Jun 18, 2026

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

  • Review of preclinical studies and clinical trials involving stem/progenitor cell therapies for HIE.
  • Analysis of data from animal models investigating the efficacy and mechanisms of various stem cell types (e.g., umbilical cord blood cells, mesenchymal stem cells, NSCs).
  • Evaluation of NSC migration, differentiation, and neuroprotective effects in HIE models.

Main Results:

  • Human umbilical cord blood mononuclear cells and mesenchymal stem/progenitor cells demonstrate therapeutic potential in HIE models via local and peripheral mechanisms.
  • Neural stem/progenitor cells (NSCs) transplanted in HIE models exhibit long-distance migration to ischemic areas and differentiate into neurons.
  • Studies highlight the need for further research to address critical questions before clinical application.

Conclusions:

  • Stem cell transplantation holds promise for neuroprotection and regeneration in neonatal HIE.
  • Understanding the endogenous regenerative potential of the neonatal brain and optimizing cell therapy strategies are crucial for clinical translation.
  • Further investigation is required to establish the safety and efficacy of cell therapies for HIE and encephalopathy of prematurity.